Vermillion to Report Third Quarter 2017 Financial Results and Host Investor Conference Call on November 8th

VRML — 3Q17 Save-the-Date

Vermillion to Report Third Quarter 2017 Financial Results and Host Investor Conference Call on November 8th

 AUSTIN, Texas, October 25, 2017 — Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its third quarter 2017 financial results on Wednesday, November 8, 2017, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.

Wednesday, November 8 @ 4:30pm Eastern Time

Domestic:                   888-417-2254

International:             719-325-4794

Conference ID:           4929135

Webcast:                    http://public.viavid.com/index.php?id=126293

Replays, available through November 22:

Domestic:                   844-512-2921

International:             412-317-6671

Replay PIN:                4929135

 

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops and delivers innovative diagnostic and technology tools that help women with serious diseases. The company’s initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a second generation OVA1 (MIA2G) test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.

 

Investor Relations Contact:

Michael Wood

LifeSci Advisors LLC

Tel 1-646-597-6983

mwood@lifesciadvisors.com